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ABSTRACT 
Objective: The present research work aims at describing the formulation, optimization and evaluation of ion activated ocular in-situ gel of 
gatifloxacin for treatment of bacterial conjunctivitis so as to overcome patient inconvenience, precorneal drug elimination, variation in efficacy, 
vision blurring and frequent instillation associated with conventional eye drops and ointments. 
Methods: In-situ gel was prepared using gellan gum as an ion activated phase transition polymer and HPMC K100M as release retardant. 
Gatifloxacin was characterized by spectrophotometry. Crystalline state of the drug was determined using X Ray Diffraction study. The developed 
formulation exhibited instantaneous gel formation in simulated lacrimal fluid (pH 7.4), which was further evaluated for its rheology, irritancy 
parameters, in vitro release, trans-corneal permeation and antimicrobial activity. 
Results: Gatifloxacin exhibited λmax 286 nm obeying Beer Lambert’s law and pH-dependent solubility at a pH range of 2 to 4. 0.6% gellan gum and 
0.4% HPMC K100M were optimized in the formulation which exhibited a viscosity of 55 cps in sol form and 325 cps in gel form with pseudoplastic 
behavior and prolonged in vitro release. Permeation of formulation was 75.8% in 7 h with log P of drug 0.59. Developed isotonic and non-irritant 
formulation had a lower apparent permeability coefficient of 8.15 x 10-5 cm/sec as compared to marketed formulation. 
Conclusion: A Formulation can be viewed as an efficacious medicine by virtue of its higher zone of inhibition, ability to enhance precorneal 
residence time and consequently ocular bioavailability with lesser frequency of administration attributed to slow and prolonged diffusion of the 
drug from the polymeric solutions. 
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INTRODUCTION 
The term “conjunctivitis” encompasses a broad group of conditions 
referred as inflammation of the conjunctiva. The inflammation can 
be hyperacute, acute or chronic and infectious or noninfectious in 
origin. Conjunctivitis is the most common cause of red-eye. Most 
frequently, conjunctivitis (and thus red eye) is caused by bacterial or 
viral infection [1]. Bacterial conjunctivitis is usually caused by 
Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus 
species, Pseudomonas aeruginosa, and Chlamydia trachomatis [2-4]. 
Topical administration of eye drops in the lower cul-de-sac is the 
most common method of drug delivery for the treatment of ocular 
disease [5]. However, one of the major problems encountered with 
the eye drops is the rapid and extensive elimination induced by tear 
turnover, blinking, and drainage of formulation, which leads to short 
precorneal residence time and poor ocular bioavailability. As a 
result, frequent instillation of eye drops is needed in order to 
achieve the desired drug concentration and therapeutic effect [6]. An 
increase in dosing frequency or use of the highly concentrated 
solution to compensate for short ocular residence time is 
undesirable because of poor patient compliance and risk of toxicity 
due to ophthalmic absorption via the nasolacrimal duct [7]. To 
increase ocular bioavailability and duration of drug action, various 
ophthalmic vehicles, i.e., viscous solutions [8], ointments/gels [9], 
and polymer inserts [10] have been used. These ocular drug delivery 
systems, however, have not been used extensively owing to some 
drawbacks, such as blurred vision from ointments, lack of patient 
compliance from inserts and sticking of eyelids from the gel.  
An ideal ophthalmic dosage form is one that can sustain the drug 
release and remain in pre-corneal contact for an extended period of 
time. A significant increase in the residence time of the formulation 
and consequently, drug bioavailability can be achieved by delivery 
systems based on the concept of in-situ gelation [11]. These delivery 
systems consist of polymers that exhibit sol to gel phase transition due 
to changes in specific physiological conditions (pH, temperature and 
ionic strength) in the eye [12]. Depending upon the method employed 
to cause a phase transition on ocular surface, three types of systems 
are recognized, i.e., pH triggered systems-cellulose acetate hydrogen 
phthalate latex [13] and Carbopol [14-16], temperature-dependent 
systems-pluronic [17-19] and tetronics [20] and ion activated 
systems-gellan gum [21, 22] and sodium alginate [23]. Smart 
polymeric systems represent promising means of delivering the drugs; 
these polymers undergo sol-gel transition, once administered. 
Gatifloxacin is a fourth-generation flouroquinolone antibiotic used 
for the treatment of bacterial conjunctivitis. It is commercially 
available in the form of an eye drops and ointment. The topical 
ophthalmic administration of 0.3% gatifloxacin solution is indicated 
in case of severe infection. 
The objective of the present work involved the development of an 
in-situ gel formulation using an ion-activated phase transition 
polymer to effectively deliver the drug into the eye for sustained 
drug release and enhanced ocular drug bioavailability.  
MATERIALS AND METHODS 
Materials 
Gatifloxacin was used as an active pharmaceutical ingredient and was 
procured as a gift sample from M/s. Alkem Laboratories Ltd (Mumbai, 
India). Gellan gum and HPMC were procured from Chempure 
(Mumbai, India) and Colorcon Asia Pvt. Ltd. (Mumbai, India), 
respectively. The nutrient agar medium was purchased from Hi-Media 
(India). Microbial strains were available at ISF Moga to perform the 
study, which was procured from MTCC Chandigarh. Whole eyeballs of 
goat were procured from the slaughter house. All the other reagents 
were used in the present study were of analytical grade.  
Preformulation studies 
Determination of λ max by UV spectrophotometer  
One hundred mg of gatifloxacin drug powder was accurately 
weighed and transferred to a 100 ml volumetric flask. It was 
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dissolved in an adequate amount of distilled water and the volume 
was made up to 100 ml with distilled water so as to obtain a stock 
solution of 1000 µg/ml [24]. A dilution of 20 µg/ml concentration 
was made from the above stock solution with the distilled water and 
the resulting solution was scanned on a double-beam UV-visible 
spectrophotometer (Shimadzu 1700) between wavelength ranges of 
200 nm to 400 nm [25]. 
Infrared spectral analysis of gatifloxacin drug sample  
Gatifloxacin powder sample was compressed into a pellet al. ong 
with KBr (KBr pellet technique) using a shimadzu hydraulic press 
[26]. The FTIR spectrum of the drug was recorded between the 
wavenumber regions of 500-4000 cm-1 on an FTIR spectro-
photometer (Shimadzu) [27]. 
Melting point determination 
The melting point of gatifloxacin was determined using the open 
capillary method. The drug sample was filled into a capillary and 
placed in a Thiel’s tube filled with liquid glycerol. The tube was 
heated and the temperature at which the drug melted was noted. 
X-ray diffraction study of gatifloxacin drug sample 
X-ray diffraction analysis was performed using Rigaku 
diffractometer (high beam monochromatic) using Cu Kα radiation, 
which was generated at 40 Kv and 100 mA at λ 1.5418Å. The data 
were collected over an angular range from 5-30ᵒ in a continuous 
mode.  
Analytical method development 
Preparation of calibration curve of gatifloxacin in distilled 
water 
Ten mg of gatifloxacin drug sample was accurately weighed and 
transferred into a 100 ml volumetric flask. It was dissolved in an 
adequate amount of distilled water and the volume was made up to 
100 ml with distilled water to obtain a stock solution of 100 µg/ml. 
Appropriate dilutions were made in distilled water from the above 
stock solution in the concentration range of 2-14 µg/ml and were 
analyzed spectrophotometrically at 286 nm against a blank 
prepared in the same manner. The absorbance data for different 
concentrations were subjected to regression analysis. 
Preparation of calibration curve of gatifloxacin in simulated 
lacrimal fluid 
Ten mg of gatifloxacin drug sample was accurately weighed and 
transferred into a 100 ml volumetric flask. It was dissolved in an 
adequate amount of distilled water and the volume was made up to 
100 ml to obtain a stock solution of 100µg/ml. Appropriate dilutions 
were made in simulated lacrimal fluid from the above stock solution 
the concentration range of 2-14 µg/ml and were analyzed 
spectrophotometrically at 286 nm against a blank prepared in the 
same manner. The absorbance data for different concentrations 
were subjected to regression analysis. 
Partition coefficient (Log P) determination 
The partition coefficient (P) is the quotient of two concentrations and 
is usually given in the form of its logarithm to base 10 (log P). Partition 
coefficient of the gatifloxacin drug sample was determined by 
saturating 10 ml of octanol with 10 ml of distilled water for 30 min. 
Twenty mg of the drug was added to this blend and was moderately 
shaken for 1 hour with 5 min interval. The two solvent layers were 
separated through separating funnel and separately filtered through a 
Whatman® filter paper No 41 and the amount of gatifloxacin dissolved 
in each phase, was determined spectrophotometrically at 286 nm 
against reagent blank prepared in the same manner on a UV-visible 
spectrophotometer (Shimadzu 1700). 
Solubility studies 
The solubility of the gatifloxacin drug sample was determined in 
distilled water, buffer solutions of pH 1.2, 2.0, 4.0, 6.0, 7.4, 1% 
Tween 80, disodium edetate, and simulated lacrimal fluid. An excess 
amount of drug was placed into suitable screw-cap vials containing 
10 ml of each solvent, as mentioned above. The vials were properly 
sealed and vortexed for 10 min. They were placed on the orbital 
flask shaker (Khera Instruments Pvt. Ltd. India) at room 
temperature for 24 h. Then the samples were filtered, suitably 
diluted, and analyzed spectrophotometrically using a UV-visible 
spectrophotometer (Shimadzu 1700) at 286 nm.  
Preparation of formulations 
Boric acid and disodium edetate were dissolved in distilled water. 
Gellan gum and HPMC were then dissolved in the above solution. The 
required quantity of gatifloxacin to give a final drug concentration of 
0.3% w/v was added to the polymeric solution and stirred until 
dissolved and then phenylmercuric nitrate was added to it as a 
preservative. The formulations were filled amber colored glass vials, 
closed with rubber closures and sealed with aluminum caps. The 
formulations, in their final pack, were terminally sterilized by 
autoclaving at 121 °C temperature, 15 psi pressure for 15 min. The 
sterilized formulations were stored in a refrigerator until further use.  
Gelation studies 
The gelation studies were carried out in cylindrical tubes, which 
were filled with 5 ml of simulated lacrimal fluid (SLF). 50 µl of the 
formulation containing ponceau red dye was added with a 
conventional dropper to a tube containing SLF and was then visually 
assessed for the gel formed and time for gelation as well as time is 
taken for the gel formed to dissolve. 
Evaluation of formulations 
Physiochemical characterization 
The clarity of the formulation was evaluated by visual observation 
against white and black backgrounds for presence of any particulate 
matter. pH of the formulations was determined by pH meter 
(Cyberscan 510). 
Drug content uniformity 
Drug content analysis of prepared in-situ gelling systems was carried 
out using a spectrophotometric method. The assay of these 
formulations was carried out by diluting equivalent of 100 µl of 
(Gatifloxacin) the formulation to 25 ml with distilled water in the 
sterilized volumetric flask. The absorbance was estimated 
spectrophotometrically at 286 nm by using a double-beam UV-
visible spectrophotometer (Shimadzu 1700). 
Viscosity and rheology 
The viscosity of the formulation was determined by Brookfield 
Viscometer (LVT model) [13]. To assess the gelation of formulation 
on instillation and mixing with lacrimal fluid, the viscosity 
measurements were also taken after diluting the formulation with 
the simulated lacrimal fluid (SLF). SLF comprised of 0.670 g sodium 
chloride, 0.200 g sodium bicarbonate and 0.008 g calcium chloride 
dihydrate and distilled water q. s to 100 g, which simulated the 
cation content of lacrimal fluid [19, 31]. Viscosity of the sample 
solution was measured over a range of 0.3 to 30 rpm speed. The 
hierarchy of speed was reversed from 30 to 0.3 rpm. The average of 
the two dial readings was used to calculate the viscosity. 
Gel consistency test 
The firmness, consistency and cohesiveness of hydrogels are 
assessed using a texture analyzer, which mainly indicates the flow 
behavior of sol so the formulation can be easily administered in vivo. 
Higher values of adhesiveness of gels are needed to maintain 
intimate contact with surfaces like tissues [32]. Gel consistency was 
studied using Texture Analyzer TA-XT Plus (Stable Microsystems). 
Gelation of the formulation was induced by adding SLF to it. A test 
was carried out in a standard back extrusion rig using 50 mm 
(diameter) container filled approximately up to 75% with the 
formulation. An extrusion disc of 45 mm diameter was positioned 
centrally over the sample container. The probe used was calibrated 
for the force and distance measurement before use [33]. Positive 
area in the graph represents consistency and positive force 
represents firmness of sample. Negative area represents an index of 
viscosity and negative force represents cohesiveness. 
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Isotonicity evaluation  
Isotonicity, which is an important characteristic of the ophthalmic 
formulations, had to be maintained to prevent tissue damage and 
irritation to the eye. Smear of resuspended RBCs with gatifloxacin 
in-situ gel formulation was prepared and observed under the 
polarizing microscope (Leica) at 45x magnification [34, 35]. The 
same procedure was followed for the marketed gatifloxacin eye 
drops (GatiquinTM), isotonic solution (negative control) as well as 
hypertonic and hypotonic solution (positive controls). Size and 
shape of the RBCs with developed gatifloxacin in-situ gel formulation 
was compared to that with marketed gatifloxacin eye drops 
(GatiquinTM) as well as with the positive and negative controls.  
In vitro drug release study 
The in vitro drug release of the gatifloxacin in-situ gel formulation was 
estimated using modified USP dissolution apparatus-1 (Electrolab). 
Whatman® filter paper No 41 was placed in the USP basket. It was 
then wetted by dipping in a solution of simulated lacrimal fluid for one 
minute to ensure the intimate contact of the release medium with the 
formulation. Then 100 µl of the formulation was applied to it. Fifty ml 
of simulated lacrimal fluid was filled in a beaker and the basket was 
rotated over its surface. A3-3 ml aliquots of samples were withdrawn 
at regular time intervals and replaced with an equal volume of fresh 
simulated lacrimal fluid. The samples were analyzed spectro-
photometrically for gatifloxacin content using double beam UV-visible 
spectrophotometer (Shimadzu 1700) at 286 nm. 
Kinetic modeling 
To study the release kinetics, data obtained from in vitro drug 
release studies were plotted as log cumulative percentage drug 
release versus log time to obtain a Korsmeyer Peppas plot. As the 
exponent n was 0.493 and y = 0.493x+0.734 R² = 0.989, it 
represented non fickian diffusion [36, 37]. 
In vitro trans corneal permeation study 
Whole eyeballs of goat were procured from slaughterhouse and 
safely transported to laboratory in cold condition. The corneas were 
carefully removed along with 5-6 mm of surrounding sclera and 
washed with cold saline solution. The washed corneas were stored 
in cold, freshly prepared solution simulated lacrimal fluid. Cornea 
was tied to one end of the hollow cylindrical glass tube and then its 
surface was wet by applying 14 µl of simulated lacrimal fluid to 
simulate the physiological condition of the eyes. [19] 100 µl of 
developed gatifloxacin in-situ gel formulation was spread over the 
corneal surface. The cylinder was then dipped into 50 ml of SLF 
maintained at 37±0.5◦C so as to keep the corneal surface in contact 
with SLF stirred by rotation at 50 RPM. A 3-3 ml aliquots of fluid 
were withdrawn at fixed time intervals over a period of 7 h and was 
replaced with an equal volume of fresh SLF maintained at the same 
temperature. Aliquots of withdrawn samples were analyzed for drug 
content using a double beam UV-visible spectrophotometer 
(Shimadzu 1700) at 286 nm. 
In vitro antimicrobial efficacy study 
In vitro antimicrobial efficacy study was carried out to ascertain the 
biological activity of ophthalmic sol-to-gel system against 
microorganisms. It was performed by an agar diffusion test using a 
cup-plate technique [19]. As gatifloxacin shows activity for both 
gram-positive and gram-negative microorganisms, Staphylococcus 
aureus (ATCC 25923) and Pseudomonas aeruginosa (ATCC27853) 
were used for the study. Strains were available at ISF Moga, which 
were procured from MTCC Chandigarh and are used for the present 
study. Developed gatifloxacin in-situ gel formulation, marketed eye 
drops of gatifloxacin (GatiquinTM) and placebo was poured in cups 
bored into the sterile nutrient agar previously seeded with 
Pseudomonas aeruginosa (ATCC 27853) and Staphylococcus aureus 
(ATCC 25923). After allowing diffusion of solution for 2 h, the agar 
plates were incubated at 37±0.5 ᵒC for 24 h. The entire operation 
except the incubation was carried out under laminar airflow unit. 
Ocular irritation study (HET-CAM test) 
In developing a novel ophthalmic delivery system, an injury to the eye 
was taken into consideration. Since, eye being a sensitive, most 
delicate and yet most valuable of the sense organs, the injuries to the 
Cornea, Conjunctiva, and Iris were measured according to HET-CAM 
test (Hen’s Egg Test-Chorio Allantoic Membrane). The potential ocular 
irritancy of a test substance was measured by its ability to induce 
toxicity in the Chorio Allantoic Membrane of a chick embryo [15, 23]. 
Fertilized hen’s eggs weighing between 50-60 g were procured from a 
poultry farm. The eggs were then candled to discard the defective ones 
and were then incubated in a humidified incubator at 37 ᵒC 
temperature and 75±5% RH. The trays containing eggs were rotated 
manually in a gentle manner every hour. After ninth days, a window 
(2x2 cm) was cut on the pointed end of eggs through which 0.2 ml of 
gatifloxacin in-situ gel formulation was instilled. A 0.9% NaCl solution 
was used as a negative control because it is reported to be practically 
non-irritant being isotonic and physiologically compatible and 1% 
NaOH as a positive control in the present study. After instillation of the 
formulations, the scores were recorded [38, 39]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Determination of λ max By UV spectrophotometer  
The characterization of the gatifloxacin drug sample was done using 
spectrophotometric analysis. Gatifloxacin solution was scanned on a 
double-beam UV-visible spectrophotometer (Shimadzu 1700) 
between wavelength range of 200 nm to 400 nm as shown in fig. 1 and 
exhibited λmax 286 nm which matches with the spectrum of gatifloxacin 
as reported in the literature [24, 25]. So, this wavelength was used for 
the analysis of gatifloxacin solutions throughout the studies. 
 
 
Fig. 1: UV spectrum of gatifloxacin drug sample in distilled water 
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Infrared spectral analysis of gatifloxacin drug sample  
Infrared spectrum of the gatifloxacin drug sample showed 
absorption bands for carbonyl group of quinone (1631 cm-1), 
methoxy group (2802 cm-1), unsaturation (3010 and 3076 cm-1), 
secondary amide (3404 cm-1), aromatic tertiary amine C-N stretch 
(1363 cm-1), and Ar-F (1209 cm-1) as represented in fig. 2. It 
confirms the structure of drug as IUPAC name represents 1-
cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(methylpiperazin-1-
yl)-4-oxo-3-qunolinecarboxylic acid sesquihydrate [26]. Additional 
fluorine atom is present at position 6 of the quinolone core, which 
affects the pharmacokinetic profile of fluoroquinolones in polar 




Fig. 2: FTIR spectrum of gatifloxacin drug sample 
 
 
Fig. 3: X-ray diffractogram of gatifloxacin drug sample 
 
Melting point determination 
The melting point range of the gatifloxacin sample was founded 
around 180-183 °C, which is very close to the theoretical melting 
point i.e., 182-185 °C indicating gatifloxacin with high purity [26]. 
X-ray diffraction study of gatifloxacin drug sample 
The X-ray diffractograms in fig. 3 represents the values of scattering 
angles (2θ), the inter planer d-spacings (d-value), and the relative 
intensities (I/Iο), which were automatically obtained on a digital 
printer and confirmed the crystalline structure of gatifloxacin drug 
sample [28]. It was inferred that the procured drug sample was of 
pure gatifloxacin sesquihydrate. 
Analytical method development 
Preparation of calibration curve of gatifloxacin in distilled water 
Appropriate dilutions were made in distilled water in the 
concentration range of 2-14 µg/ml and were analyzed 
spectrophotometrically at 286 nm against a blank prepared in the 
same manner. The absorbance data for different concentrations 
were subjected to regression analysis. The observations are 
graphically represented in fig. 4. Equation of the line and R-square 
value was found to be. Conc. = 0.087 * A, R=0.999. The linearity of 
the calibration curves showed that Beer Lambert’s law was obeyed 
in the concentration range of 4-14 µg/ml at λmax 286 nm 
Preparation of calibration curve of gatifloxacin in simulated 
lacrimal fluid 
Calibration curves of gatifloxacin in the simulated lacrimal fluid as 
represented in fig. 5 was prepared using a double beam UV-visible 
spectrophotometer (Shimadzu 1700). The linearity of the calibration 
curves showed that Beer Lambert’s law was obeyed in the 
concentration range of 2-14 µg/ml at λmax 286 nm. Equation of the 
line and R-square value was found to be. Conc. = 0.097 * A, R=0.999. 
The linearity of the calibration curves showed that Beer Lambert’s 
law was obeyed in the concentration range of 4-14 µg/ml at λmax 286 
nm.
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Fig. 4: Calibration curve of gatifloxacin in distilled water at 286 nm (mean±SD, n=3) 
 
 
Fig. 5: Calibration curve of gatifloxacin in the simulated lacrimal fluid at 286 nm (mean±SD, n=3) 
 
Table 1: Solubility of gatifloxacin drug sample in different solvent media 
S. No. Solvent Amount of drug dissolved (mg/ml) Inference [30] 
1 Distilled water 2.56±0.7 Slightly soluble 
2 Hydrochloric acid buffer (pH 1.2) 64.3±1.2 Soluble 
3 Hydrochloric acid buffer (pH 2.0) 56.8±0.9 Soluble 
4 Acetate buffer (pH 4.0) 44.4±0.9 Soluble 
5 Phosphate buffer (pH 6.0) 7.6±0.5 Slightly soluble 
6 Phosphate buffer (pH 7.4) 3.73±0.1 Slightly soluble 
7. Simulated lacrimal fluid 3.81±0.2 Slightly soluble 
The values are expressed as mean±SD= Standard Deviation from the mean, n=3 
 
 
Fig. 6: pH dependent solubility profile of gatifloxacin drug sample (mean±SD, n=3) 
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Partition coefficient (Log P) determination 
The Partition coefficient was calculated as the ratio of concentration 
of the drug in octanol to the concentration of the drug in water and 
then its logarithm was taken. The octanol-water partition coefficient 
(log P) of drug sample was found to be 0.59, which was similar to the 
calculated value from its structure, i.e., ClogP 0.6 and also matches 
with that reported in the literature [29].  
Solubility studies 
It was also found that gatifloxacin having a crystalline structure 
exhibit pH-dependent solubility with an aqueous solubility of 40-60 
mg/ml at a pH range of 2 to 4 as represented in table 1 and fig. 6. 
Preparation and optimization of formulation 
Composition of in-situ gelling formulations is represented in table 2. 
Gellan gum was selected as an ion activated phase transition polymer 
for gel formation in-situ. Different concentrations of gellan gum, i.e., 
0.1-0.7% were evaluated for the gelling property in physiological 
conditions. Out of which, only gellan gum solution of 0.6% exhibited 
desirable flow characteristics and resulted in instantaneous gelation in 
simulated lacrimal fluid, which was retained for an extended period of 
time as shown in table 3. Buffer solutions were earlier tried to impart 
the buffering capacity in the formulation, but that was found to result 
into gel formation due to probable interaction between ions and gellan 
gum. As isotonicity is a desirable attribute of an ophthalmic 
formulation, sodium chloride and boric acid were studied as an 
isotonicity adjusting agents. Since, gel formation was observed in the 
formulation containing sodium chloride hence boric acid was selected 
as an isotonicity adjusting agent. Phenyl mercuric nitrate was used as 
a preservative in the formulation. A 0.05% of disodium edetate was 
also added to enhance the solubility of gatifloxacin in water and 
prevent its crystallization in freeze-thaw conditions. HPMC K100M 
was incorporated as a release retardant in the formulation. The 
formulations, in their final pack were terminally sterilized by 
autoclaving at 121 °C temperature, 15 psi pressure for 15 min. The 
sterilized formulations were stored in a refrigerator until further use. 
Composition of formulations is mentioned as below in table 2. 
 
Table 2: Composition of prepared in-situ gelling formulations 
Ingredients Amount (g) 
F 1 F 2 F 3 F 4 F 5 
Gatifloxacin 0.3 0.3 0.3 0.3 0.3 
Gellan gum 0.6 0.6 0.6 0.6 0.6 
Boric acid 1.68 1.68 1.68 1.68 1.68 
Phenylmercuric nitrate 0.002 0.002 0.002 0.002 0.002 
Disodium edetate 0.05 0.05 0.05 0.05 0.05 
HPMC K100M - 0.3 0.4 0.5 0.6 
Distilled water 100 100 100 100 100 
 
Gelation studies  
Different concentrations of gellan gum, i.e., 0.1-0.7% were evaluated for 
the gelling property in physiological conditions. Out of which, only gellan 
gum solution of 0.6% exhibited desirable flow characteristics and 
resulted in instantaneous gelation in the simulated lacrimal fluid, which 
was retained for an extended period of time. The grading of gelling 
capacity is based up on the time taken to form the gel and time taken to 
dissolve the gel in simulated tear fluid. Formulations with good gelling 
capacity exhibit that gelation remains for longer periods once it occurs. 
 
Table 3: Gel formation of Gellan Gum with simulated lacrimal fluid (SLF) 
Concentration of gellan gum Gelling property in SLF 
0.1% no gelation 
0.2% no gelation 
0.3% immediate gelation for few minutes 
0.4% immediate gelation for few minutes 
0.5% immediate gelation for few minutes 
0.6% immediate gelation which last longer 
0.7% immediate gelation which last longer 
 
Table 4: Drug content uniformity 
Formulation code Drug content (%±SD) 
F 1 99.3±0.45 
F 2 97.8±0.11 
F 3 98.7±0.75 
F 4 96.0±0.60 
F 5 97.1±0.05 
 The values are expressed as mean±SD Standard Deviation from the mean, n=3 
 
Evaluation of formulations 
Physiochemical characterization 
The designed formulation was found to be clear by visual 
examination against white and black backgrounds. The pH of the 
formulation was determined to be between 6.2-6.3 by using pH 
meter (Cyberscan® 510). Formulations resulted in gel formation in 
SLF, clearly indicating phase transition behavior in the physiological 
conditions of the eye.  
Drug content uniformity 
Drug content uniformity was found to be between 98.7±0.75 to 
99.6±0.84 % (Shimadzu 1700) at 286 nm as shown in table 4. 
Viscosity and rheology 
Viscosity of the formulation was determined by Brookfield 
viscometer (LVT). The formulation exhibited a viscosity of 55 cps in 
solution form and 325 cps in gel form at 12 rpm. There were 6 folds 
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increase in the viscosity of gel as compared to its sol form. It 
exhibited pseudoplastic behavior as there was shear thinning with 
the increase of angular velocity. 
Gel consistency test 
The developed formulation was further subjected to gel consistency 
studies on Texture Analyzer (TA-XT Plus). The consistency, firmness 
and cohesiveness of in-situ gelling system are assessed by using this 
device. Higher values of adhesiveness of gels are needed to maintain 
intimate contact with the mucus surface. Gel formed in simulated 
lacrimal fluid exhibited a consistency of 216.59 gm. sec, firmness 
28.344 gm, index of viscosity 37.465 gm. sec, and cohesiveness-
17.896 gm as shown in table 5 and fig. 7. The purpose of texture 
analyses was to provide information about the mechanical 
properties of samples. These properties can be directly correlated 
with sensory parameters in vivo and, therefore, are valuable in the 
development of products with desirable attributes that contribute to 
patient acceptability and compliance. 
 
Table 5: Results of gel consistency test of developed gatifloxacin in-situ gel formulation 
Area F-T 1:2 gm. sec Area F-T 3:4 gm. sec Force 1 gm Force 2 gm 
216.592 -37.465 28.344 -17.896 
 




















Fig. 7: Gel consistency test of developed gatifloxacin in-situ gel formulation 
 
Isotonicity evaluation  
Gatifloxacin in-situ gel formulation was found to be isotonic, as it 
exhibited no change in the size and shape of RBCs. The formulation was 
evaluated for the isotonicity and was also compared with the marketed 
eye drops, isotonic solution (negative control), hypertonic and hypotonic 
solution (positive controls). There was no change in the shape of the 
RBCs after the addition of developed gatifloxacin in-situ gel formulation, 
while hypertonic solution resulted in shrinkage of the cells and 
hypotonic solution caused the bursting of the cells.  
Hence, it was confirmed that the formulation was isotonic to the eyes. It 
was also compared with that of marketed gatifloxacin eye drops 
(GatiquinTM) as shown in fig. 8. 
 
 
Fig. 8: (a) RBCs with developed in-situ gel formulation of gatifloxacin F3, (b) RBCs with marketed gatifloxacin eye drops (GatiquinTM), (c) 
RBCs with isotonic 
 
In vitro drug release study  
Combination of 0.6% gellan gum and 0.4% HPMC was selected, as it 
had satisfactory attributes of in-situ gelling property, flow 
characteristics and prolonged in vitro release over the duration of 8 
h with 90.6% release as shown in fig. 9. 
Kinetic modeling  
Data obtained from in vitro drug release studies were plotted as log 
cumulative percentage drug release versus log time, which is Korsmeyer 
Peppas plot [36, 37] as shown in fig. 10. As the exponent n was 0.493, it it 
followed the anomalous transport. The drug release pattern obtained for 
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the gelled samples as represented in fig. 9 and fig. 10 are characteristic 
for hydrophilic matrices. It is rapid in the beginning and proceeds at a 
rate that declined with time. When the formulation comes in contact 
with the simulated lacrimal fluid and gelation occurs, a pre-hydrated 
matrix is formed in which hydration and water penetration no longer 
limit drug release, leading to an apparent diffusion-controlled release. As 
gellan gum is a biodegradable polymer, it followed diffusion and matrix 
erosion of HPMC occurred due to hydrolytic cleavage of polymer chains 
and the result of kinetic data revealed that gatifloxacin followed zero-
order release kinetics independent of time. 
 
 
Fig. 9: In vitro drug release profile of gatifloxacin in-situ gel formulation in simulated lacrimal fluid (SLF) (mean±SD, n=6) 
 
 
Fig. 10: Representation of korsmeyer peppas plot (mean±SD, n=6) 
 
In vitro trans corneal permeation study  
Tran’s corneal drug permeation study for gatifloxacin in-situ gel 
formulation was performed in the SLF (pH 7.4 and 37±0.5 °C) which 
exhibited the delayed release of drug from the polymeric matrix. The 
in vitro trans corneal permeation study across excised goat’s cornea 
exhibited 74.8% drug permeability in 7 h with an apparent 
permeability coefficient of 8.25 x 10-5 cm/sec. Prolonged precorneal 
retention in the conjunctival sac and slow drug release from the 
formulation could impart improved in vivo ocular bioavailability. 
In vitro antimicrobial efficacy study  
Diameter of the zone of inhibition observed with the developed 
formulation was higher as shown in fig. 11 than that of marketed 
preparation Gatiquin TM. Overall values of the diameter of the zone of 
inhibition against P. aeruginosa (6.6 cm) were higher than that of S. 
aureus (4.3 cm). The highest values obtained for the developed 
formulation in comparison to the marketed eye drops, which was 5.3 
cm for P. aeruginosa and 4 cm for S. aureus could be attributed to 
slow and prolonged diffusion of the drug from the polymeric 
solutions. 
Ocular irritation study (HET-CAM test) 
Developed formulation was also found to be non-irritant to eyes. It 
was tested for irritation on the Chorio Allantoic Membrane of the 
chick embryo, which is a complete tissue, including veins, arteries 
and capillaries and responds to injury with a complete inflammatory 
process, a process similar to that induced in the conjunctival tissue 
of rabbit eyes [15, 23]. Each CAM was observed for 5 min after 
instillation for hemorrhage, coagulation and vessel lysis [40, 41]. 
Gatifloxacin in-situ gel formulation was found to be non-irritant to 
eyes exhibiting mean score of zero in HET-CAM test for ocular 
irritancy for 5 min as shown in table 6. Since the immune response 
generated by chorioallantoic membrane of chicken simulates the 
ocular immune response of the human eye, the developed 
formulation can be presumed to be non-irritant to the eyes. 
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Fig. 11: Zone of inhibition exhibited by the developed gatifloxacin in-situ gel formulation F3 and marketed eye drop (GatiquinTM) 
 
Table 6: Observations for HET-CAM test 
Test substance Score Inference 
0.9% NaCl 0 Non-irritant 
Developed Formulation 0 Non-irritant 
1 % NaOH 14.27 Severe irritant 
 
CONCLUSION 
On the basis of observation made and results obtained, it can be 
concluded that the developed gatifloxacin in-situ gel formulation can 
overcome the drawbacks of the conventional ocular dosage forms. 
The developed formulation provided efficient therapy through the 
prolonged drug release of the drug over an 8 h period in vitro. A 
formulation could be easily removed from the package, presented a 
good spreadability on the corneal surface and adhere to the mucous 
layer without disintegrating, in order to prolong retention time. It 
exhibited better antimicrobial efficacy when compared with the 
marketed eye drops. The formulation was isotonic and devoid of any 
irritant effect to the eyes. The ease of administration, along with its 
ability to provide sustained release could result in a decrease in the 
frequency of administration thus enhancing patient compliance. 
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